• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Dow Dips 200 Points; TJX Posts Upbeat Sales

    2/28/24 10:12:21 AM ET
    $ADIL
    $BETS
    $IAS
    $OGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Restaurants
    Consumer Discretionary
    Get the next $ADIL alert in real time by email

    U.S. stocks traded lower this morning, with the Dow Jones index falling around 200 points on Wednesday.

    Following the market opening Wednesday, the Dow traded down 0.52% to 38,770.83 while the NASDAQ fell 0.63% to 15,933.71. The S&P 500 also fell, dropping, 0.33% to 5,061.21.

    Check This Out: Robinhood, Shake Shack And 2 Other Stocks Insiders Are Selling

     

    Leading and Lagging Sectors

     

    Energy shares rose by 0.5% on Wednesday.

    In trading on Wednesday, information technology shares fell by 0.8%.

     

    Top Headline

     

    The TJX Companies, Inc. (NYSE:TJX) posted better-than-expected sales for its fourth quarter on Wednesday.

    TJX Companies posted GAAP earnings of $1.12 per share, in-line with market estimates. The company’s quarterly sales came in at $16.40 billion, versus expectations of $16.21 billion.

    TJX said it sees FY25 earnings of $3.94 to $4.02 per share, versus estimates of $4.11 per share. The company expects consolidated comparable store sales gaining 2% to 3%.

     

    Equities Trading UP

     

    Vivani Medical, Inc. (NASDAQ:VANI) shares shot up 390% to $4.9478 after the company announced preclinical data on weight loss effects for NPM-115 and disclosed that semaglutide is the active pharmaceutical ingredient in NPM-139.

    Shares of Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) got a boost, surging 124% to $1.8969. Adial Pharmaceuticals secured new US patent covering lead product for alcohol use disorder.

    Bit Brother Limited (NASDAQ:BETS) shares were also up, gaining 63% to $4.0617.

     

    Equities Trading DOWN

     

    Oragenics, Inc. (NYSE:OGEN) shares dropped 45% to $1.35. Oragenics priced its public offering 1.4 million common shares at $1.50 per share for gross proceeds of $2.1 million.

    Shares of Integral Ad Science Holding Corp. (NASDAQ:IAS) were down 39% to $10.39 after the company reported fourth-quarter financial results.

    Palatin Technologies, Inc. (NYSE:PTN) was down, falling 36% to $2.55 after the company reported results of PL9643 MELODY-1 pivotal Phase 3 clinical trial in patients with dry eye disease.

    Also Check This Out: Top 3 Energy Stocks That Could Sink Your Portfolio In Q1

     

    Commodities

     

    In commodity news, oil traded up 0.8% to $79.53 while gold traded down 0.2% at $2,040.70.

    Silver traded fell 0.8% to $22.575 on Wednesday while copper fell 0.7% to $3.8255.

     

    Euro zone

     

    European shares were mostly lower today. The eurozone’s STOXX 600 fell 0.4%, London’s FTSE 100 fell 0.7% while Spain’s IBEX 35 Index fell 0.3% The German DAX gained 0.1% French CAC 40 fell 0.1% while Italy’s FTSE MIB Index declined 0.3%.

    The services confidence indicator in the Eurozone fell to 6 in February, the lowest in three months, while economic sentiment indicator fell to 95.4 in February. The consumer confidence indicator in the Eurozone increased by 0.6 points to a reading of -15.5 in February.

     

    Asia Pacific Markets

     

    Asian markets closed lower on Wednesday, with Japan’s Nikkei 225 falling 0.08%, Hong Kong’s Hang Seng Index dipping 1.51%, China’s Shanghai Composite Index tumbling 1.91% and India’s S&P BSE Sensex falling 1.08%.

    Hong Kong’s GDP increased by 4.3% year-over-year in the fourth quarter, up from a 4.1% increase in the prior period. The index of leading economic indicators in Japan was revised higher to 110.2 in December versus preliminary reading of 110, while index of coincident economic indicators was revised lower to 115.9 in December versus a flash reading of 116.2.

     

    Economics

     

    U.S. mortgage applications fell by 5.6% on the week ending Feb. 23.

    The US economy grew an annualized 3.2% in the fourth quarter, versus a 4.9% rate in the previous quarter.

    The U.S. trade deficit in goods rose to $90.20 billion in January versus a revised $87.89 billion in the prior month.

    U.S. wholesale inventories declined by 0.1% month-over-month in January following a 0.4% increase a month ago.

    Now Read This: Cramer Says This AI Stock Is Just An Nvidia Play, Prefers This Stock Over Anheuser-Busch

    Get the next $ADIL alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ADIL
    $BETS
    $IAS
    $OGEN

    CompanyDatePrice TargetRatingAnalyst
    TJX Companies Inc.
    $TJX
    2/26/2026$170.00 → $175.00Outperform
    Telsey Advisory Group
    TJX Companies Inc.
    $TJX
    1/8/2026Buy
    Deutsche Bank
    Palatin Technologies Inc.
    $PTN
    12/12/2025$60.00Buy
    Laidlaw
    TJX Companies Inc.
    $TJX
    12/10/2025$175.00Buy
    Guggenheim
    Palatin Technologies Inc.
    $PTN
    12/3/2025$50.00Buy
    Alliance Global Partners
    TJX Companies Inc.
    $TJX
    11/20/2025$155.00 → $170.00Outperform
    Telsey Advisory Group
    TJX Companies Inc.
    $TJX
    10/15/2025$165.00Buy
    BTIG Research
    TJX Companies Inc.
    $TJX
    9/5/2025Buy
    Erste Group
    More analyst ratings

    $ADIL
    $BETS
    $IAS
    $OGEN
    SEC Filings

    View All

    Oragenics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - ORAGENICS INC (0001174940) (Filer)

    4/13/26 8:30:17 AM ET
    $OGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Adial Pharmaceuticals Inc filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - ADIAL PHARMACEUTICALS, INC. (0001513525) (Filer)

    4/9/26 5:00:08 PM ET
    $ADIL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Oragenics Inc. filed SEC Form 8-K: Shareholder Director Nominations, Financial Statements and Exhibits

    8-K - ORAGENICS INC (0001174940) (Filer)

    3/31/26 4:05:26 PM ET
    $OGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADIL
    $BETS
    $IAS
    $OGEN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Williams Gregg

    4 - Vivani Medical, Inc. (0001266806) (Issuer)

    4/16/26 6:30:10 AM ET
    $VANI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 4 filed by Benjamin Peter

    4 - TJX COMPANIES INC /DE/ (0000109198) (Issuer)

    4/14/26 5:00:08 PM ET
    $TJX
    Clothing/Shoe/Accessory Stores
    Consumer Discretionary

    SEC Form 4 filed by Canestrari Kenneth

    4 - TJX COMPANIES INC /DE/ (0000109198) (Issuer)

    4/14/26 5:00:02 PM ET
    $TJX
    Clothing/Shoe/Accessory Stores
    Consumer Discretionary

    $ADIL
    $BETS
    $IAS
    $OGEN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Adial Pharmaceuticals Successfully Completes Manufacturing of Demonstration Batch Production, Enabling Clinical and Registration Production for AD04 Planned Phase 3 Trial

    GLEN ALLEN, Va., April 22, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, announced the successful completion of the demonstration batch production for AD04. The results of the batch confirmed that the transferred process met the targeted specifications for the planned Phase 3 clinical batch (and registration campaign) and matched the dissolution profile of the previous Phase 2 batch, thereby demonstrating a successful technical process transfer. This important step was required prior to manufacturing

    4/22/26 9:35:00 AM ET
    $ADIL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Oragenics Reports 8 study drug doses in Phase IIa Clinical Trial of ONP-002 for Mild Traumatic Brain Injury

    • Enrollment underway at Mackay Base Hospital in Queensland, Australia; additional sites in final activation stages SARASOTA, Fla., April 20, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE:OGEN), a clinical-stage biotechnology company developing brain-targeted therapeutics through proprietary intranasal delivery technology, today announced that 2 patients and 8 study drug doses have been administered in its ongoing Phase IIa clinical trial evaluating ONP-002, the Company's lead candidate for the treatment of mild traumatic brain injury (mTBI) a.k.a., concussion. Enrollment is progressing at Mackay Base Hospital in Queensland, Australia, the first activated site in the trial, with addition

    4/20/26 9:00:00 AM ET
    $OGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Oragenics Doses First Patient in Phase IIa Clinical Trial of ONP-002 for Mild Traumatic Brain Injury

    Mackay Base Hospital activated March 31, 2026 as first clinical trial site; first patient dosed within days of activation — a signal of strong enrollment velocity and significant unmet medical need SARASOTA, Fla., April 13, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE:OGEN), a clinical-stage biotechnology company developing brain-targeted therapeutics through proprietary intranasal delivery technology, today announced that the first patient has been dosed in its ongoing Phase IIa clinical trial evaluating ONP-002, the Company's lead candidate for the treatment of concussion and mild traumatic brain injury (mTBI). The milestone was achieved at Mackay Hospital in Australia — the first sit

    4/13/26 8:30:00 AM ET
    $OGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADIL
    $BETS
    $IAS
    $OGEN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Telsey Advisory Group reiterated coverage on TJX with a new price target

    Telsey Advisory Group reiterated coverage of TJX with a rating of Outperform and set a new price target of $175.00 from $170.00 previously

    2/26/26 6:42:28 AM ET
    $TJX
    Clothing/Shoe/Accessory Stores
    Consumer Discretionary

    Deutsche Bank initiated coverage on TJX

    Deutsche Bank initiated coverage of TJX with a rating of Buy

    1/8/26 10:58:50 AM ET
    $TJX
    Clothing/Shoe/Accessory Stores
    Consumer Discretionary

    Laidlaw initiated coverage on Palatin Technologies with a new price target

    Laidlaw initiated coverage of Palatin Technologies with a rating of Buy and set a new price target of $60.00

    12/12/25 8:54:18 AM ET
    $PTN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADIL
    $BETS
    $IAS
    $OGEN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Williams Gregg bought $1,683,335 worth of shares (1,575,231 units at $1.07) (SEC Form 4)

    4 - Vivani Medical, Inc. (0001266806) (Issuer)

    3/16/26 6:15:46 AM ET
    $VANI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Director Williams Gregg bought $1,983,333 worth of shares (1,866,492 units at $1.06) (SEC Form 4)

    4 - Vivani Medical, Inc. (0001266806) (Issuer)

    2/17/26 6:01:47 AM ET
    $VANI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Director Lane Amy B gifted 174 shares and bought $7,915 worth of shares (116 units at $68.23), decreasing direct ownership by 3% to 29,007 units (SEC Form 4)

    4 - TJX COMPANIES INC /DE/ (0000109198) (Issuer)

    2/3/26 7:00:03 PM ET
    $TJX
    Clothing/Shoe/Accessory Stores
    Consumer Discretionary

    $ADIL
    $BETS
    $IAS
    $OGEN
    Financials

    Live finance-specific insights

    View All

    The TJX Companies, Inc. Announces 13% Increase in Common Stock Dividend

    The TJX Companies, Inc. (NYSE:TJX) today announced that its Board of Directors has raised the amount of its quarterly dividend by 13% from the last dividend paid. The Board declared a regular quarterly dividend in the amount of $.48 per share, payable June 4, 2026, to shareholders of record on May 14, 2026. Ernie Herrman, Chief Executive Officer and President of The TJX Companies, Inc., stated, "I am pleased to announce that our Board of Directors has approved a 13% increase in our quarterly dividend. This marks our 29th dividend increase over the last 30 years. Over this period, TJX's dividend has grown at a compound annual rate of 20%. In addition, we plan to continue our significant sh

    3/30/26 11:19:00 AM ET
    $TJX
    Clothing/Shoe/Accessory Stores
    Consumer Discretionary

    The TJX Companies, Inc. Reports Q4 and Full Year FY26 Results; Q4 Comp Sales Growth, Pretax Profit Margin, and Diluted EPS All Well Above Plan; Expects to Increase Dividend by 13% and Buy Back $2.50 to $2.75 Billion of Stock in FY27

    Q4 and full year FY26 adjusted results throughout this press release exclude a net benefit from a litigation settlement related to credit card interchange fees and related expenses (see below) Q4 consolidated comparable sales increased 5%, well above the Company's plan Q4 pretax profit margin of 13.5%, up 1.9 percentage points versus last year Q4 adjusted pretax profit margin of 12.2%, up 0.6 percentage points versus last year and well above the Company's plan Q4 diluted earnings per share were $1.58, up 28% versus last year Q4 adjusted diluted earnings per share were $1.43, up 16% versus last year and well above the Company's plan Full year FY26 consolidated comparable sa

    2/25/26 7:30:00 AM ET
    $TJX
    Clothing/Shoe/Accessory Stores
    Consumer Discretionary

    The TJX Companies, Inc. to Report Q4 & Full Year FY26 Results February 25, 2026

    The TJX Companies, Inc. (NYSE:TJX) today announced that it plans to release its fourth quarter and full year Fiscal 2026 sales and earnings results on Wednesday, February 25, 2026, before 9:30 a.m. ET. At 11:00 a.m. ET that day, Ernie Herrman, TJX's Chief Executive Officer and President, will hold a conference call to discuss the Company's fourth quarter and full year Fiscal 2026 results, operations, and business trends. A real-time webcast of the call will be available to the public at TJX.com. A replay of the call will also be available by dialing (866) 367-5577 (toll free) or (203) 369-0233 through Tuesday, March 3, 2026, or at TJX.com. About The TJX Companies, Inc. The TJX Compani

    2/11/26 11:30:00 AM ET
    $TJX
    Clothing/Shoe/Accessory Stores
    Consumer Discretionary

    $ADIL
    $BETS
    $IAS
    $OGEN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Oragenics Inc.

    SC 13G/A - ORAGENICS INC (0001174940) (Subject)

    11/14/24 7:29:57 PM ET
    $OGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Integral Ad Science Holding Corp.

    SC 13G/A - INTEGRAL AD SCIENCE HOLDING CORP. (0001842718) (Subject)

    11/14/24 6:19:26 PM ET
    $IAS
    Computer Software: Programming Data Processing
    Technology

    Amendment: SEC Form SC 13G/A filed by Oragenics Inc.

    SC 13G/A - ORAGENICS INC (0001174940) (Subject)

    11/14/24 3:59:00 PM ET
    $OGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADIL
    $BETS
    $IAS
    $OGEN
    Leadership Updates

    Live Leadership Updates

    View All

    IAS APPOINTS MELISSA FURZE AS HEAD OF DATA SCIENCE

    Former LinkedIn executive to scale IAS's data science and AI capabilities worldwide NEW YORK, Dec. 22, 2025 /PRNewswire/ -- Integral Ad Science (NASDAQ:IAS), a leading global media measurement and optimization platform, today announced that Melissa Furze joined the company as Head of Data Science at IAS reporting to the Chief Technology Officer. Melissa will lead the company's global data science, AI, and analytics strategy, partnering closely with product, engineering, and the commercial teams to accelerate innovation, strengthen protection and performance capabilities, and deliver trusted, data-driven outcomes for advertisers and publishers worldwide.

    12/22/25 8:00:00 AM ET
    $IAS
    Computer Software: Programming Data Processing
    Technology

    TJ Maxx Hits the Road with the First-Ever "Maxxinista Express" Holiday Tour Inspired by its Iconic Superfans

    A one-of-a-kind double-decker tour bus experience will travel across the country with festive stops in three cities to amp up the fun of holiday shopping at multiple TJ Maxx stores in search of the best finds and gifts FRAMINGHAM, Mass., Dec. 4, 2025 /PRNewswire/ -- This holiday season, TJ Maxx (NYSE:TJX) is gifting Maxxinistas a magical experience with the debut of the Maxxinista Express, a first-of-its-kind double-decker bus taking superfans on a TJ Maxx road trip in select cities throughout December. The festive tour will bring select fans into a Maxxinista wonderland amidst a full day of shopping with stops at three beloved TJ Maxx stores in their cities so they can hunt for thoughtful g

    12/4/25 11:16:00 AM ET
    $TJX
    Clothing/Shoe/Accessory Stores
    Consumer Discretionary

    Vivani Medical Provides Business Update Including $10M Equity Financing and Reports Second Quarter 2025 Financial Results

    Company plans rapid advancement of semaglutide implant NPM-139, following positive weight loss data from an ongoing preclinical study of NPM-139 and promising results from the LIBERATE-1 Phase 1 clinical study of NPM-115 New $10M equity financing to enable accelerated development of NPM-139 while securing financial position into the second half of 2026 Vivani to spin off Cortigent, Inc., a division of the Company that develops brain implant devices to help patients recover critical body functions, as an independent publicly traded company ALAMEDA, Calif., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ:VANI) ("Vivani" or the "Company"), a biopharmaceutical company

    8/13/25 4:20:00 PM ET
    $VANI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care